PapersFlow Research Brief
Bladder and Urothelial Cancer Treatments
Research Guide
What is Bladder and Urothelial Cancer Treatments?
Bladder and urothelial cancer treatments are evidence-based interventions including surgery, chemotherapy, immunotherapy, and targeted therapies administered based on clinical stage to manage urothelial carcinoma, which constitutes over 90% of bladder cancers.
The field encompasses 115,019 works with established treatments like radical cystectomy and emerging immunotherapies such as PD-L1 blockade and checkpoint inhibitors. "Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients" (Stein et al., 2001) reports outcomes in 1,054 patients undergoing uniform surgical treatment with pelvic lymph node dissection. "Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial" (Rosenberg et al., 2016) demonstrates efficacy of atezolizumab in platinum-refractory cases.
Research Sub-Topics
Immunotherapy in Urothelial Carcinoma
This sub-topic covers immune checkpoint inhibitors like PD-1/PD-L1 blockers (atezolizumab, pembrolizumab) for advanced bladder cancer. Researchers study response predictors, combination therapies, and resistance mechanisms post-platinum chemotherapy.
Radical Cystectomy Outcomes
This sub-topic examines surgical resection for muscle-invasive bladder cancer, including long-term survival, complications, and urinary diversion techniques. Researchers analyze risk factors for recurrence and quality-of-life impacts.
Intravesical Therapy for Non-Muscle Invasive Bladder Cancer
This sub-topic focuses on BCG immunotherapy and chemotherapeutic instillations to prevent recurrence and progression in Ta/T1 tumors. Researchers investigate optimal schedules, resistance, and alternatives like device-assisted therapies.
Molecular Subtyping of Urothelial Carcinoma
This sub-topic classifies bladder tumors into luminal, basal, and other subtypes via genomics and transcriptomics. Researchers correlate subtypes with prognosis, therapy response, and targeted opportunities.
Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer
This sub-topic evaluates cisplatin-based regimens (MVAC, gemcitabine-cisplatin) before cystectomy to improve survival. Researchers assess pathological response rates, biomarkers, and integration with immunotherapy.
Why It Matters
Treatments directly impact survival in urothelial carcinoma patients, with radical cystectomy providing long-term control in invasive cases as shown in 1,054 patients (Stein et al., 2001). Immunotherapies extend survival: pembrolizumab increased overall survival by approximately 3 months compared to chemotherapy in platinum-refractory advanced urothelial carcinoma (Bellmunt et al., 2017), while NICE-approved Padcev (enfortumab vedotin) plus Keytruda (pembrolizumab) doubles survival rates for over a thousand NHS patients annually and serves as the first perioperative regimen improving outcomes over surgery alone in cisplatin-ineligible muscle-invasive cases (FDA approval, 2025). These advances address progression after platinum chemotherapy, as in atezolizumab trials (Rosenberg et al., 2016), enabling first-line use of combinations in metastatic settings.
Reading Guide
Where to Start
"Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients" (Stein et al., 2001) first, as it provides foundational long-term surgical outcomes in 1,054 patients, establishing associations between tumor stage, lymph node status, and survival essential for understanding standard care.
Key Papers Explained
"Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients" (Stein et al., 2001) sets surgical benchmarks, which "Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables" (Sylvester et al., 2006) extends to non-muscle-invasive risk stratification in 2596 patients. "Comprehensive molecular characterization of urothelial bladder carcinoma" (Weinstein et al., 2014) adds genomic layers, while "TGFβ attenuates tumour response to PD-L1 blockade" (Mariathasan et al., 2018) explains immunotherapy resistance mechanisms building on molecular insights. Clinical trials like "Atezolizumab..." (Rosenberg et al., 2016) and "Pembrolizumab as Second-Line Therapy..." (Bellmunt et al., 2017) validate these in advanced settings.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Recent preprints highlight biomarker-driven therapies targeting FGFR3 mutations and immune checkpoint inhibitors for advanced urothelial carcinoma, alongside toxicity profiles of new agents like enfortumab vedotin combinations. NICE and FDA approvals of Padcev-Keytruda as first-line and perioperative treatments mark shifts in metastatic and muscle-invasive management.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | TGFβ attenuates tumour response to PD-L1 blockade by contribut... | 2018 | Nature | 5.2K | ✓ |
| 2 | Atezolizumab in patients with locally advanced and metastatic ... | 2016 | The Lancet | 3.7K | ✓ |
| 3 | Radical Cystectomy in the Treatment of Invasive Bladder Cancer... | 2001 | Journal of Clinical On... | 3.5K | ✕ |
| 4 | EAU Guidelines on Renal Cell Carcinoma: 2014 Update | 2015 | European Urology | 3.4K | ✕ |
| 5 | Pembrolizumab as Second-Line Therapy for Advanced Urothelial C... | 2017 | New England Journal of... | 3.3K | ✓ |
| 6 | EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screenin... | 2016 | European Urology | 3.2K | ✓ |
| 7 | Natural History of Progression After PSA Elevation Following R... | 1999 | JAMA | 3.1K | ✕ |
| 8 | Comprehensive molecular characterization of urothelial bladder... | 2014 | Nature | 3.0K | ✓ |
| 9 | Predicting Recurrence and Progression in Individual Patients w... | 2006 | European Urology | 2.9K | ✕ |
| 10 | EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Up... | 2020 | European Urology | 2.7K | ✕ |
In the News
NICE recommends breakthrough life-extending combination treatment for advanced bladder cancer.
NICE has recommended a new first-line treatment for adults with advanced bladder cancer, marking a significant breakthrough for patients facing this devastating disease.
NHS England » New hope for bladder cancer patients as breakthrough treatment doubles survival
Change my preferencesI'm OK with analytics cookies **More than a thousand patients living with bladder cancer every year can now receive a breakthrough treatment that can double survival rates fro...
Padvec–Keytruda combination approved by NICE for ...
**NICE has approved the use of Padcev™ (enfortumab vedotin) with Keytruda® (pembrolizumab) as a first-line treatment for adults with metastatic urothelial cancer.**
U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer
- _PADCEV plus Keytruda is the first and only approved perioperative treatment regimen that can significantly improve survival over current standard of care (surgery alone) in cisplatin-ineligible ...
Four Big Things in Bladder Cancer Care to Watch for in 2026
First-line treatment for advanced urothelial carcinoma (UC) is increasingly defined by immunotherapy-based combinations, with enfortumab vedotin (Padcev) plus pembrolizumab (Keytruda; EV-pembro) we...
Code & Tools
This repository contains the classifier code (written in R), the TCGA 2017 data required by the classifer, example expression data and the classifi...
## Repository files navigation # BLCAsubtyping Transcriptomic tools to classify bladder tumours according to six published molecular classificati...
2 - How to use This codebase presents a two-part framework for image analysis, comprising a tissue segmentation module for segmenting tissue regi...
This repo presents steps needed to make sense of single-cell RNA sequencing (scRNA) data. I used a scRNA dataset coming from Zhaohui Chen _et al._ ...
Recent Preprints
(PDF) Ivermectin induces cell cycle arrest and caspase ...
Bladder carcinoma is one of the most common malignancies worldwide, and >90% of all bladder cancers are classified as urothelial carcinomas(UC). Surgery, radiotherapy, chemotherapy, targeted thera...
Advances in the management of localized bladder cancers
this Review, we discuss progress and changes in the management of localized bladder cancer over the past decade and highlight ongoing innovations and future research directions that will shape clin...
Towards biomarker-driven therapies for urothelial carcinoma
Molecularly targeted agents and immune checkpoint inhibitors (ICIs) are transforming the treatment landscape for patients with advanced-stage urothelial carcinoma (aUC), although trials testing the...
Bladder cancer - Latest research and news
The management of localized bladder cancers is rapidly evolving. In this Review, the authors discuss diagnostic innovations, refinements in surgical approaches and novel intravesical or systemic tr...
Toxicity Profile of New Therapies in Metastatic Urothelial ...
The introduction of new therapies has revolutionized the landscape of urothelial carcinoma, with a significant impact on patient survival. However, the optimal therapeutic sequence has yet to be de...
Latest Developments
The latest developments in bladder and urothelial cancer treatments research as of February 2026 include the routine use of immunotherapy-based combinations such as enfortumab vedotin (Padcev) plus pembrolizumab (Keytruda; EV-pembro) for advanced urothelial carcinoma, with ongoing interest in antibody-drug conjugates, HER2-targeted therapies, and molecularly guided approaches in later lines of care (oncologynewscentral.com, mayoclinic.org).
Sources
Frequently Asked Questions
What is the role of radical cystectomy in invasive bladder cancer?
Radical cystectomy with pelvic lymph node dissection treats invasive bladder cancer, with long-term results reported in 1,054 patients linking primary tumor stage and lymph node status to outcomes (Stein et al., 2001). This surgery serves as a standard for muscle-invasive disease.
How does atezolizumab benefit patients with metastatic urothelial carcinoma?
Atezolizumab provides treatment for locally advanced and metastatic urothelial carcinoma patients who progressed after platinum-based chemotherapy, as shown in a phase 2 trial (Rosenberg et al., 2016). It offers a single-arm, multicentre option post-platinum failure.
What survival advantage does pembrolizumab offer in advanced urothelial carcinoma?
Pembrolizumab as second-line therapy significantly prolongs overall survival by approximately 3 months over chemotherapy in platinum-refractory advanced urothelial carcinoma, with fewer treatment-related adverse events (Bellmunt et al., 2017).
How does TGFβ influence response to PD-L1 blockade?
TGFβ attenuates tumour response to PD-L1 blockade by excluding T cells from the tumour microenvironment (Mariathasan et al., 2018). This mechanism contributes to resistance in bladder cancer immunotherapy.
What predicts recurrence in stage Ta T1 bladder cancer?
EORTC risk tables predict recurrence and progression in individual stage Ta T1 bladder cancer patients, based on a combined analysis of 2596 patients from seven trials (Sylvester et al., 2006).
What molecular insights guide urothelial bladder carcinoma treatment?
Comprehensive molecular characterization reveals subtypes and targets in urothelial bladder carcinoma (Weinstein et al., 2014), supporting precision approaches.
Open Research Questions
- ? How can TGFβ-mediated T cell exclusion be overcome to enhance PD-L1 blockade efficacy?
- ? Which biomarkers best predict response to second-line pembrolizumab in platinum-refractory cases?
- ? What lymph node dissection extent optimizes outcomes post-radical cystectomy?
- ? How do molecular subtypes from TCGA characterization inform personalized therapies?
- ? Which factors most accurately predict progression in Ta T1 bladder cancer using EORTC tables?
Recent Trends
NICE and FDA approvals of Padcev (enfortumab vedotin) plus Keytruda (pembrolizumab) as first-line for metastatic urothelial cancer and perioperative for cisplatin-ineligible muscle-invasive cases double survival rates for over a thousand patients yearly.
Preprints emphasize biomarker-driven therapies like FGFR3-targeted agents, evolving localized management with immunotherapies and antibody-drug conjugates, and toxicity sequencing of novel treatments.
Research Bladder and Urothelial Cancer Treatments with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Bladder and Urothelial Cancer Treatments with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.